A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

被引:64
|
作者
Singh, Dig Vijay [1 ]
Mete, Uttam Kumar [1 ]
Mandal, Arup Kumar [1 ]
Singh, Shrawan Kumar [1 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Urol, Chandigarh 160012, India
关键词
Tamsulosin; Tadalafil; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Erectile Dysfunction; Medical Therapy; COMBINED ORAL-THERAPY; ERECTILE DYSFUNCTION; PHOSPHODIESTERASE-5; INHIBITORS; INTEGRATED APPROACH; SILDENAFIL CITRATE; SEXUAL DYSFUNCTION; ALPHA-BLOCKERS; MEN; EPIDEMIOLOGY; ALFUZOSIN;
D O I
10.1111/jsm.12357
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age. Aim To evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH. Methods In this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg/day alone (Group A), 44 patients received tadalafil 10 mg/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment. Main Outcome Measures There were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event. Results A significant improvement in IPSS score was observed in all the 3 groups A, B, and C (-50.90%, P<0.05; -33.50%, P<0.05; and -53.90%, P<0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P<0.05; +45.96%, P<0.05; and +60.23%, P<0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P<0.05; 29.78%, P<0.05; and 37.04%, P<0.05) and (-60.90%, P<0.05; -49.45%, P<0.05; and -62.97%, P<0.05, respectively). The QoL scores improved significantly (-73.35%, P<0.05; -70.26%, P<0.05; and -79.65%, P<0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events. Conclusions In patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone.
引用
收藏
页码:187 / 196
页数:10
相关论文
共 50 条
  • [1] Comparative study of tamsulosin, tadalafil, and combination of tamsulosin with tadalafil in the treatment of patients with lower urinary tract symptoms
    Mondal, Soumya
    Agarwal, Neeraj
    Pal, Dilip Kumar
    UROLOGICAL SCIENCE, 2024, 35 (02) : 90 - 94
  • [2] Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
    Ahmad, Malik Suhail
    Dar, Yaser Ahmad
    Khawaja, Abdul Rauf
    Para, Sajad Ahamd
    Malik, Sajad Ahamd
    Wani, Mohammad Saleem
    Bhat, Arif Hamid
    Wani, Prince Muzaffar
    UROLOGY ANNALS, 2022, 14 (03) : 236 - 240
  • [3] Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study
    Pogula, Vedamurthy Reddy
    Kadiyala, Lalith Sagar
    Gouru, Vijayabhaskar Reddy
    Challa, Sivasankar Reddy
    Byram, Ranadheer
    Bodduluri, Sudeep
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2019, 72 (01) : 44 - 50
  • [4] Randomized Controlled Trial to Assess the Efficacy of the Combination Therapy of Alfuzosin and Tadalafil in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
    Kumar, Santosh
    Kondareddy, Chilekampalli
    Ganesamoni, Raguram
    Nanjappa, Bhuvanesh
    Singh, Shrawan K.
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2014, 6 (01) : 35 - 40
  • [5] A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia
    Zhou, Rui
    Che, Xuanyan
    Zhou, Zhongbao
    Ma, Yue
    AMERICAN JOURNAL OF MENS HEALTH, 2023, 17 (01)
  • [6] Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
    Zhou, Zhongbao
    Zheng, Xuesong
    Wu, Jitao
    Gao, Zhenli
    Xu, Zhunan
    Cui, Yuanshan
    AMERICAN JOURNAL OF MENS HEALTH, 2019, 13 (05)
  • [7] The Study of Tadalafil and Tamsulosin as Monotherapy for Lower Urinary Tract Symptoms Due to Benign Hyperplasia of Prostate
    Selvaraj, Sudhakaran
    Sivalingam, Senthil Kumar
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (52): : 3968 - 3971
  • [8] Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial
    Nagasubramanian, Santhosh
    John, Nirmal Thampi
    Antonisamy, Belavendra
    Mukha, Rajiv Paul
    Berry, Chandra Singh Jeyachandra
    Kumar, Santosh
    Devasia, Antony
    Kekre, Nitin Sudhakar
    BJU INTERNATIONAL, 2020, 125 (05) : 718 - 724
  • [9] Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial
    Sebastianelli, Arcangelo
    Spatafora, Pietro
    Frizzi, Jacopo
    Saleh, Omar
    Sessa, Maurizio
    De Nunzio, Cosimo
    Tubaro, Andrea
    Vignozzi, Linda
    Maggi, Mario
    Serni, Sergio
    McVary, Kevin T.
    Kaplan, Steven A.
    Gravas, Stavros
    Chapple, Christopher
    Gacci, Mauro
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [10] A Randomized, Placebo-Controlled Study to Assess Safety and Efficacy of Vardenafil 10 mg and Tamsulosin 0.4 mg vs. Tamsulosin 0.4 mg Alone in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
    Gacci, Mauro
    Vittori, Gianni
    Tosi, Nicola
    Siena, Giampaolo
    Rossetti, Mario Alberto
    Lapini, Alberto
    Vignozzi, Linda
    Serni, Sergio
    Maggi, Mario
    Carini, Marco
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 (06) : 1624 - 1633